-
Oxford BioDynamics Joins MTPA and MGH in the REFINE-ALS Study
Oxford BioDynamics will join Mitsubishi Tanabe Pharma America and Massachusetts General Hospital in the REFINE-ALS study, analyzing disease biomarkers. Click here to read more about this partnership.
What do you think of this news?
Sorry, there were no replies found.
Log in to reply.